Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02607163
Other study ID # 4-2015-0672
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 2015
Est. completion date March 6, 2019

Study information

Verified date September 2019
Source Yonsei University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Acute kidney injury(AKI) is a common and severe complication after the cardiac surgery. Postoperative AKI increases the in-hospital stay, intensive care unit(ICU) stay and postoperative mortality. Aortic surgery is the most risky surgery that causes the postoperative AKI, and the incidence of AKI after aortic surgery is about 50%.

The α1- and α2-adrenergic receptors in the kidney modulate vasoconstrictor and vasodilatory effects, respectively. Agents that attenuate renal vasoconstriction may have potential as renoprotective drugs because vasoconstriction most likely contributes to the pathophysiology of AKI. Clonidine, an α2-agonist, has been shown experimentally to inhibit renin release and cause a diuresis, and it has been evaluated in an experimental AKI model, confirming its potential as a renoprotective agent. Furthermore, it has been already reported that dexmedetomidine, α2-agonist, reduce the impairment of renal function after cardiac operation.

The aim of this study is to examine the association between preoperative dexmedetomidine infusion and the incidence of postoperative acute kidney injury(AKI) in patients undergoing aortic surgery.


Recruitment information / eligibility

Status Completed
Enrollment 108
Est. completion date March 6, 2019
Est. primary completion date March 6, 2019
Accepts healthy volunteers No
Gender All
Age group 20 Years to 100 Years
Eligibility Inclusion Criteria:

1. the patients undergoing ascending, arch and/or proximal descending aorta surgery with cardiopulmonary bypass

2. 20 - 100 yrs old

Exclusion Criteria:

1. having preoperative severe renal dysfunction (eGFR < 15 ml/min per 1.73m2)

2. Left ventricular-ejection fraction < 30%

3. Preexisting congestive heart failure

4. Severe coronary artery disease

5. Hemodynamically unstable arrhythmia

6. Cardiogenic shock during perioperative period

7. Ventricular assist device use

8. cannot communication because of a language barrier or illiteracy

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
dexmedetomidine
Immediately after the induction of anesthesia, patients in the dexmedetomidine group received dexmedetomidine continuous intravenous (IV) infusion of 0.4 mcg/kg/h until 24 hours after surgery.
saline
same infusion rate (received equal volume of normal saline), IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery.

Locations

Country Name City State
Korea, Republic of Department of Anesthesiology and Pain Medicine, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine Seoul

Sponsors (1)

Lead Sponsor Collaborator
Yonsei University

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Acute kidney injury (AKI) after aortic surgery (AKI according to the Kidney Disease Improving Global Outcomes (KDIGO) criteria) 0.3 mg/dl increase in serum creatinine concentration within 48 hours OR, a 50% increase within 7 days postoperatively OR, urine volume < 0.5 ml/kg/h for 6 hours up to 7 days after the aortic surgery
Secondary Acute kidney injury (AKI) after aortic surgery (AKI according to the Kidney Disease Improving Global Outcomes (KDIGO) criteria) KDIGO stage 2: Serum creatinine increase to 2-3-fold from baseline OR urine output < 0.5 ml/kg/h for 12h up to 7 days after the surgery
Secondary Acute kidney injury (AKI) after aortic surgery (AKI according to the Kidney Disease Improving Global Outcomes (KDIGO) criteria) KDIGO stage 3: Serum creatinine increase to 3.0-fold from baseline OR Increase in serum creatinine to = 4 mg/dl OR Initiation of renal replacement therapy OR In patients <18 years, decrease in eGFR to < 35 ml/min per 1.73 m2 OR Anuria for = 12h. up to 7 days after the surgery
Secondary major morbidity endpoint acute kidney injury (same as the primary endpoint), permanent stroke, prolonged ventilator care >24h, deep wound infection, and mortality. acute kidney injury - up to 7 days after the surgery; Other - during the hospitalization for surgery
Secondary postoperative delirium delirium - assessed with The American Psychiatric Association's fifth edition of the Diagnostic and Statistical Manual of Mental Disorders or Confusion Assessment Method for the ICU up to 7 days after the surgery
Secondary drug-related adverse events hypotension (mean arterial pressure <60 mmHg) or bradycardia (<50 beats/min) OR the use of vasopressor, inotropes or temporary pacing, OR postoperative arrhythmia hypotension or bradycardia: during surgery; Other - during surgery and 24 hours after surgery